Pharma & Biotech

BioNTech is executing a deliberate strategy to evolve beyond its identity as a COVID-19 vaccine specialist and refocus on its...

Shares of Viking Therapeutics, a clinical-stage biotechnology firm, experienced a significant rally, closing at $34.34 with a gain of approximately...

The final chapter for Tübingen-based mRNA pioneer CureVac on public markets is now written. A turbulent period in German stock...

A notable shift is occurring in the shareholder base of IQVIA Holdings Inc., the global provider of advanced analytics, technology...

The final chapter has closed for CureVac as a publicly traded entity. The German biotech firm, once a beacon of...

In a strategic pivot aimed at capturing a broader patient base, Novo Nordisk is aggressively promoting a new oral version...

The independent public trading story for CureVac has reached its conclusion. BioNTech's successful takeover has led to a suspension of...

Pfizer Inc. used the prominent J.P. Morgan Healthcare Conference to detail its future roadmap, but the market's response has been...

After a prolonged period of significant share price declines, Sangamo Therapeutics is back in the spotlight following a critical regulatory...

The remarkable ascent of Eli Lilly's stock has hit a potential stumbling block. Following months of impressive gains, the equity...